D
David J. Kuter
H指数:61
被引数:2.2万
浏览量:0
个人简介
暂无内容
教育背景
暂无内容
工作经历
暂无内容
荣誉奖项
暂无内容
Clinical activity and safety of rilzabrutinib in patients with previously treated immune thrombocytopenia (LUNA3): results from the open-label period of a phase 3 trial
利扎布鲁替尼在既往治疗过的免疫性血小板减少症患者中的临床活性和安全性(LUNA3):一项III期试验开放标签期的结果
Lancet Haematology
IF17.7
Supportive strategies in thrombocytopenia: Platelet transfusion and beyond
血小板减少症的支持性策略:血小板输注及其它方法
Blood Reviews
IF5.7
The hunt for a cure: modern medical approaches for immune thrombocytopenia
寻找治疗方法:免疫性血小板减少症的现代医学方法
Evans syndrome in pregnancy and the postpartum period: A retrospective cohort study
Evans综合征在妊娠期及产后期:一项回顾性队列研究
Evaluating rilzabrutinib in the treatment of immune thrombocytopenia
评估rilzabrutinib在免疫性血小板减少症治疗中的应用
immunotherapy
IF2.3
Safety and efficacy of daratumumab in immune thrombocytopenia
达雷木单抗在免疫性血小板减少症中的安全性与有效性
Blood Advances
IF7.1
Efficacy and Safety Results With Rilzabrutinib, an Oral Bruton Tyrosine Kinase Inhibitor, in Patients With Immune Thrombocytopenia: Phase 2 Part B Study
利扎布鲁替尼(Rilzabrutinib)的疗效和安全性结果:一项在免疫性血小板减少症患者中的口服布鲁顿酪氨酸激酶抑制剂Ⅱ期B部分研究
Clinical Burden of Illness in Patients with Persistent or Chronic Primary Immune Thrombocytopenia Treated with Advanced Therapies in the United States
美国接受先进疗法治疗的持续性或慢性原发性免疫性血小板减少症患者疾病负担研究
BLOOD
IF23.1

